Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer

  • D. S. Howard
  • , D. A. Rizzierri
  • , B. Grimes
  • , D. Upchurch
  • , G. L. Phillips
  • , A. K. Stewart
  • , J. R. Yannelli
  • , C. T. Jordan

Producción científica: Articlerevisión exhaustiva

26 Citas (Scopus)

Resumen

Gene transfer into early hematopoietic cells has been problematic due to the quiescent nature of primitive cells and the lack of gene transfer vehicles with high efficiency for hematopoietic cell types. Previously, we have shown that adenoviral vectors can be used for the transduction of normal human progenitors with gene transfer efficiencies of approximately 30%. However, this approach is limited by relatively slow uptake kinetics (24-48 h) and a strong dependence on the presence of exogenous cytokines. Thus, we have modified this approach by combining adenoviral vectors with polycations to generate a virus-polycation complex, or VPC. Vehicles of this nature, when composed of conventional adenoviral vectors and polyamidoamine dendrimers, are a highly efficient means of transducing both normal and acute myelogenous leukemia (AML) cells. Moreover, the kinetics of gene transfer are markedly increased using the VPC strategy, with approximately 70% of transduction complete within 2 h. In this study, using viruses that encode green fluorescence protein (GFP), or the T cell costimulatory molecule B7.1 (CD80), we show that VPC-mediated gene transfer is an effective means of transducing normal and AML cells, including those with a highly primitive phenotype. Our data suggest that transient genetic manipulation of primitive hematopoietic cells can readily be achieved and should therefore permit a variety of research and clinical endeavors.

Idioma originalEnglish
Páginas (desde-hasta)1608-1616
Número de páginas9
PublicaciónLeukemia
Volumen13
N.º10
DOI
EstadoPublished - 1999

Nota bibliográfica

Funding Information:
This work was supported by grants from the McDowell Cancer Foundation and the Leukemia Society of America (Translational Grant #6057-99). The authors thank the McDowell Cancer Foundation for generous support of our research efforts. We also thank Dr Stephen Szilvassy for critical reading of the manuscript and many helpful discussions, and Dr Stephen Hardy for providing the Ad-GFP virus and protocols for the use of adenoviral vectors. The Ad-B7 virus was generously provided by Dr Sophie Dessureault.

Financiación

This work was supported by grants from the McDowell Cancer Foundation and the Leukemia Society of America (Translational Grant #6057-99). The authors thank the McDowell Cancer Foundation for generous support of our research efforts. We also thank Dr Stephen Szilvassy for critical reading of the manuscript and many helpful discussions, and Dr Stephen Hardy for providing the Ad-GFP virus and protocols for the use of adenoviral vectors. The Ad-B7 virus was generously provided by Dr Sophie Dessureault.

FinanciadoresNúmero del financiador
Leukemia Society of America6057-99
McDowell Cancer Research Foundation

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Cancer Research

    Huella

    Profundice en los temas de investigación de 'Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer'. En conjunto forman una huella única.

    Citar esto